Wednesday, October 8

(The presenters of gray titles did not allow the online appearance of their lectures )

40. MOLECULAR AND CELLULAR BIOLOGY OF CANCER

ROOM A, 08.00-16.45 – Wednesday, October 8

Chair Persons: B. Kaina, M.M. Müller

Establishment of a standardized 3D in vitro tumor-stroma model. S. Hensler, B. Kotkamp, K.I. Pohl, N. Linde, D. Stoll, M.M. Müller (Furtwangen; Sigmaringen; Reutlingen, Germany; New York, NY, USA) (30’)
Production of Urocortin 1 in human malignant cell lines. Y. Manome, K. Fujioka, T. Tachibana, K. Tojo, K. Ikeda (Tokyo, Japan) (10’)
The oncogenic potential of ribonucleotide reductase M2 (RRM2) in clear cell renal cell carcinoma. M. Abudawood, N. Ahmed, Q. Wang (Manchester, UK) (30’)
Stem cell-based therapy: A double-edged sword? Z.Y. Abdel-Magee, Y. Yang, R. Thomas,M. Ranjan, D. Mondal, K. Moroz, B. Rezk, K.Moparty, A.B. Abdel-Mageed (New Orleans, LO, USA) (15’)
Expression of CRABP proteins in different types of human cancer. E. Tchevkina, Y. Kainov, I. Favorskaya, V. Delektorskaya, G. Chemeris, A. Komelkov, A. Zhuravskaya, I. Zborovskaya (Moscow, Russia) (20’)

Chair Persons: T. Isbir, Q. Wang

Mechanism of inhibition of thymidylate synthase-catalyzed reaction by N⁴-OH-_DCMP in view of crystallographic studies. W. Rode, A. Dowiercial, P. Wilk, A. Jarmula, K. Krawiec, W. Rypniewski, B. Kierdaszuk (Warsaw, Poland) (30’)
STAT3 and sphingosine-1-phosphate signaling in inflammation associated colorectal cancer. A.V. Nguyen, Y.-Y. Wu, E. Lin (Bayside, NY, USA) (30’)
Emerging roles of bioactive sphingoids in glioblastoma aggressiveness . G. Marfia, C. Di Vito, L. Abdel Hadi, S. Navone, R. Campanella, L. Riboni (Milan, Italy) (20’)
Prediction of Heat-Shock Proteins from Sequence Information. A. Jerrison, S. Seker, C. Chrysostomou, A.B. Dalan, T. Isbir (Leicester, UK; Istanbul, Turkey) (10’)

Chair Persons: F.L. Queiroga, J. Schneider

New Insights into Cox-2 pathways in cancer: the dog as a promising model. F.L. Queiroga, M.I. Carvalho, T. Raposo, J. Prada, H. Gregório, I. Pires (Vila Real, Portugal) (30’)
Mutational analysis of the APC gene in FAP-associated desmoid tumors. M.L. De Marchis, R. Palmirotta, L. Picariello, D. Della-Morte, P. Ferroni, M. Roselli, F. Tonelli, F. Guadagni (Rome; Florence, Italy) (20’)
The interplay between CD3+ T-lymphocytes and concurrent COX-2/EGFR expression in canine malignant mammary tumours. M.I. Carvalho, I. Pires, J. Prada, F.L. Queiroga(Braga, Portugal) (30’)
Thermodynamic differences between cancer and normal cells. J. Molnár, B.S. Thornton (Szeged, Hungary; Sydney, Australia) (30’)
Degarelix activity on cell growth and cell migration of three human prostate cancer cell lines. F. Iacopino, S. Sorrentino, G. Sica (Rome, Italy) (15’)
Novel telomerase activators in aging and age related diseases. E. Priel, E. Eitan, A. Tichon, I. Levi, R. Peleg, A. Gazit, S. Slavin (Beer-Sheva; Tel-Aviv, Israel) (20’)
Tryptophan metabolism, neopterin and cancer. J.M. Gostner, K. Becker, F. Ueberall, D. Fuchs (Innsbruck, Austria) (20’)
Possible contribution of BRAFV600E mutation to TGF- ß1/ NFIC dependent aberrant methylation pattern in colorectal cancer. P. Karpinski, N. Blin, M.M Sasiadek (Wroclaw, Poland) (15’)
Lung cancer incidence and survival in association to expression of anti- and pro-apoptotic proteins in chromium exposed individuals. E. Halasova, T. Matakova, T. Dzian, S. Javorkova, K. Javorka, D. Dobrota (Martin; Ružomberok, SlovakRepublic) (10’)
Osmotic stress alters the permeability of the pleura and the migration properties of mesothelial cells. V. Peppa, E. Solenov, I. Tsilioni, I. Kalomenidis, P.A.Molyvdas, K. Gourgoulianis, C. Hatzoglou, S.G. Zarogiannis (Larissa; Athens, Greece; Novosibirsk, Russia) (10’)

41. CYTOGENETICS AND GENETICS

ROOM A, 17.00-19.30 – Wednesday, October 8

Chair Persons: W. Weber, I. Kiss

Familial cancer: The alert clinician and UICC. W. Weber (Basel, Switzerland) (15’)
Role of allelic polymorphisms in the susceptibility to colorectal and head- and neck cancers. I. Kiss, Z.S. Orsós, J. Cseh, A.Csejtei, I. Szanyi, G. Pajkos, A. Németh (Pecs; Székesfehérvár; Szombathely; Kecskemét, Hungary) (20’)
Association between ERCC2 gene polymorphism and primary ovarian cancer. G. Yildirim, R. Attar, C. Fiçicioglu, Gulec-Yilmaz, Ö Timirci-Kahraman, H. Atasoy , Ö Kizilkale-Yildirim, C. Iyibozkurt, A. Buyukoren, A.B. Dalan, B. Çakmakoglu, A. Ergen, T. Isbir (Istanbul, Turkey) (20’)
Etiological observations in 7 patients with pancreatic neuroendocrine tumors (PNETs). W. Weber (Basel, Switzerland) (15’)
RRM1 and RRM2 gene polymorphisms in patients with primary ovarian cancer. R. Attar, G. Yildirim, C. Fiçicioglu, S. Gulec-Yilmaz, Ö Timirci-Kahraman, H. Atasoy, Ö Kizilkale-Yildirim, C. Iyibozkurt, A. Buyukoren, A.B. Dalan, I. Yaylim, U. Görmüs,T. Isbir (Istanbul, Turkey) (20’)
Silent mutation in HLA-E gene is associated with Tunisian nasopharyngeal cancer. H. Douik, N.A. Romdhane, C. Fortier, M. Makni, L. Harzallah, R. Khrishnammorthy, D. Charron, R. Tamouza, F. Guemira (Tunis, Tunisie; Paris, France) (15’)
Relationship of genetic polymorphism of transforming growth factor-beta1 (TGF-ß1) with urinary bladder cancer – a cases-control study on North Indian population. Kirti, S.N. Sankhwar, R. Singh, P.L. Sankhwar, A. Goel, D. Dalela (Lucknow, Uttar Pradesh, India) (10’)

42. MULTI-DRUG AND DRUG RESISTANCE: MECHANISMS AND REVERSAL

ROOM B, 8.00-12.00 – Wednesday, October 8

Chair Persons: L. Amaral, J. Molnar

Similar responses of MDR cancer and bacteria to the same inhibitor of efflux pumps in general. L. Amaral, J. Molnar (Lisbon, Portugal; Szeged, Hungary) (20’)
Heat-shock protein HSP27 in anticancer mechanisms. M.B. Stope, U. Zimmermann, R. Walther, M. Burchardt (Griefswald, Germany) (25’)
Plant-derived compounds for modulating pgp-mediated mdr in cancer cells. M.-J.U. Ferreira (Lisbon,Portugal) (30’)
Antitumour effects of selected plant polyphenols, gallic acid and ellagic acid, on sensitive and multidrug resistant leukaemia HL60 cells. A. Maruszewska, J. Tarasiuk (Szczecin, Poland) (30’)
P-glycoprotein expression is downregulated by temozolomide in glioblastoma stem cells. I.C. Salaroglio, V. Caldera, I. Campia, J. Kopecka, M. Mellai, L. Annovazzi, A. Bosia, D. Ghigo, D. Schiffer, C. Riganti (Turin; Vercelli, Italy) (10’)
Edysteroids potentiate the activity of doxorubicin in cancer. A. Martins, J. Csabi, J. Molnár, L. Amaral, A. Hunyadi (Szeged, Hungary; Lisbon, Portugal) (15’)
Multidrug resistance reversing activity of newly developed phenothiazines on p glycoprotein (ABCB1)-related resistance in different cancer models. G. Spengler, D. Takács, Z. Riedl, G. Hajós, L. Amaral, J. Molnár (Szeged; Budapest, Hungary; Lisbon, Portugal) (15’)
Semi- and total-synthetic protoflavone derivatives as MDR selective anticancer agents. B. Dankó, A. Martins, L. Amaral, J. Molnár, M. Pešic, G. Szakács, A. Hunyadi (Szeged; Budapest, Hungary; Lisbon, Portugal; Belgrade, Serbia) (15’)
SILAC-based analysis reveals a unique phosphoproteomic-signature of HER2-resistant breast cancer cells. J.F.G. Nunes, H. Zhang, J. Stebbing, N. Angelopoulos, G. Giamas (London, UK) (15’)
Effects of ABCE1 downregulation by RNAi on chemosensitivity of lung cancer cells. G. Kara, S. Tuncer, M. Turk, E.M. Denkbas (Beytepe, Ankara; Yahsihan, Kirikkale, Turkey) (15’)

43. DIAGNOSIS AND PROGNOSIS OF CANCER

ROOM B, 13.00-16.00 – Wednesday, October 8

Chair Persons: P. Ferroni, C. Sansom, G. Karanikas

Fluorodeoxyglucose uptake in advanced non-small cell lung cancer with and without pulmonary lymphangitic carcinomatosis. H. Ooi, C.Y. Chen, Y.C. Hsiao, W.S. Huang, B.T. Hsieh (Taichung, Taiwan) (40’)
Expression of antigen processing machinery components in tonsillar (TSCC) and Base Of Tongue Cancer (BOTSCC) in relation to Human Papillomavirus (HPV) and clinical outcome. T. Ramqvist, N. Tertipis, L. Haeggblom, C. Nordfors, N. Grün, A. Näsman, A. Vlastos, T. Dalianis (Stockholm, Sweden) (15’)
Clinical value of scintimammography in diagnosis, treatment monitoring and follow- up. M.R. El-Zahry, M. Rodrigues-Radischat, P. Berghammer, H. Sinzinger (Vienna, Austria) (25’) – In process
New predictors of venous thromboembolism in ambulatory cancer patients. P. Ferroni (Rome, Italy) (30’)
Evaluation of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) in detection of suspected extra adrenal paraganglioma. G. Karanikas, K. El-Rabadi, A. Khameneh, M. Weber, M. Mayerhoefer, M. Hacker (Vienna, Austria) (10’)
MicroRNAs in cerebrospinal fluid – potential diagnostic tools for CNS lymphomas. M. Chechlinska, M. Zajdel, G. Rymkiewicz, M. Cieslikowska, K. Blachnio, Z. Bystydzienski , K. Goryca, A. Druzd-Sitek, M. Sromek, J. Walewski, J.K. Siwicki (Warsaw, Poland) (10’)
Correlation of RCAS1 and CD3 expression and their clinical significance in non-small cell lung cancers. N. Tsoukalas, C. Giaginis, S. Siakavellas, I. Kostakis, M. Tolia, M. Kiakou, E. Bournakis, A. Papakostidi, I. Sfiniadakis, A. Karameris, S. Theocharis (Athens, Greece) (10’)

44. NUTRITION AND CANCER. NUTRITIONAL ASPECTS OF CANCER PREVENTION

ROOM B, 16.15-18.45 – Wednesday, October 8

Chair Person : G. Vollmer, S.A. Lamprecht, N. Abu Freha

Developmental programming in experimental breast cancer. G. Vollmer, M. Muders, O. Zierau, F.J. Möller (Dresden, Germany) (30’)
Dysmetabolism and cancer. Association and clinical outcomes. S. Riondino, P. Ferroni, R. Palmirotta, M. Roselli, F. Guadagni (Rome, Italy) (20’)
Cancer, nutrition and more: the nature-deficit-effect and the origin of cancer. J. Spitz, A. Spitz (Schlangebad, Germany) (30’)
Bacterial mutagenicity studies on bottled mineral water samples. K. Szendi, Z. Kontár, G. Gerencsér, K. Berényi, C. Varga (Pécs, Hungary) (10’)
Cytostatic drugs and dietary supplements – Clinically relevant interactions? A. Farkouh, A. Georgopoulos, M. Czejka (Vienna, Austria) (15’)
Correlations of Vitamin D blood levels with beta catenin and p53 expression in precancerous and cancerous human colon. A. Juniku-Shkololli, S. Manxhuka-Kerliu, H. Ahmetaj, V. Khare, S. Zekaj (Prishtina, Republic of Kosovo; Vienna, Austria) (10’)

45. NEW ANTICANCER AGENTS

ROOM C, 08.00-15.00 – Wednesday, October 8

Chair Persons: S. Sarkar, P. Collery

Epigenetic changes in cancer cells and development of a combination therapy. S. Sarkar (Boston, MA, USA) (30’)
Nanotherapy with empty liposomes for carcinoma. Y. Matsumoto (Kumamoto, Japan) (30’)
A novel, selective small molecule inhibitor of protein kinase CK2 induces significant cell death in vitro and in tumor xenograft models. B. Guerra, T.D.L. Rasmussen, A. Schnitzler, H.H. Jensen, B.S. Boldyreff, Y. Miyata, N. Marcussen, K. Niefind, O.G. Issinger (Odense, Denmark; Cologne, Germany; Kyoto, Japan) (40’)
Combination of three metals for the treatment of cancer: Gallium, Rhenium and Platinum. 2. The Conclusion. P. Collery, J. D’Angelo, A. Mohsen, A. Kermagoret, A. Tomas, T. Collery, M. Wei, A. Badawi, D. Desmaele (Algajola; Chatenay-Malabry; Paris; MaisonsAlfort, France; Cairo, Egypt) (20’)
Disulfiram, an anti-alcoholism drug, giving new hope to cancer patients. P. Liu, Z. Wang, S. Brown, V. Kannappan, P.E. Tawari, A.L. Armesilla, W. Wang (Wolverhampton, UK) (30’)
The effect of GcMAF complexed with oleic acid on multiple myeloma cultures. R.J. Smith, E. Ward, J.J.V. Branca, M. Ruggiero, G. Morucci, S. Pacini (Cambridge, UK; Firenze, Italy; Bayreuth, Germany) (30’)
1,4-Dihydropyridines and related compounds as potential anticancer drugs. G. Duburs, A. Krauze, E. Bisenieks, B. Vigante, A. Plotniece, I. Bruvere, S. Grinberga, I. Shestakova, I. Domracheva, E. Jaschenko, N. Zarkovic, J. Molnar (Riga, Latvia; Zagreb, Croatia; Szeged, Hungary) (30’)

Chair Persons: J. Anastassopoulou, S. Kottaridis

Tanshinone IIA could inhibit gastric carcinoma AGS cells through increasing p-p38, p-JNK and p53 but decreasing p-ERK, Cdc2 and cyclin B1 expression. C.C. Su (Changhua, Taiwan) (10’)
Protein and polymeric nanoparticles for cancer therapy: Synthesis, characterization, drug release and interaction with a breast cancer cell line (MCF-7). O. Akbal, E. Erdal, T. Vural, D. Kavaz, E.B. Denkbas (Ankara, Turkey; Nicosia, Cyprus) (15’)
Photodynamic therapy in canine and feline cancer treatment using the photosensitizer Bremachlorin. A. Roos, J.V.F.Tan, P.B.A.A. van Driel, T.J.A. Snoeks, M. van Vliet, C.G.W.M. Lowik (Gouda, Netherlands) (10’)
Oxaliplatin together with PPAR ligands induce anti-proliferative effects in human colon and prostate cancer cells. N. Strakova, J. Hofmanova, O. Zapletal, K. Soucek, R.Ferd, J. Bouchal, Z. Kolar, A. Kozubik (Brno; Olomouc, Czech Republic) (10’)
N(4)-boronated derivatives of 2’-deoxycytidine as potential BNCT agent. J. Niziol, Z. Zielinski, P. Maj, W. Rode, T. Ruman (Rzeszów; Warsaw, Poland) (15’)
Will we ever find a better anthracycline? M. Lukawska (Warsaw, Poland) (10’)

47. CANCER SURGERY

ROOM C, 15.15-19.30 – Wednesday, October 8

Chair Persons: T. Yoshizumi, N. Tsoukalas

Living donor liver transplantation for hepatocellular carcinoma within Milan criteria. T. Yoshizumi, K. Shirabe, T. Ikegami, N.Harimoto, S. Itoh, K. Takeishi, Y. Yamashita, H.Kawanaka, T. Ikeda, Y.Maehara (Fukuoka, Japan) (30’)
Clinical results of repeat hepatectomy for recurrent hepatocellular carcinoma: A single-center experience. Y. Yamashita, K. Shirabe, K. Takeishi, S. Itoh, N. Harimoto, T. Ikegami, T. Yoshizumi, H. Kawanaka, T. Ikeda, Y. Maechara (Fukuoka, Japan) (20’)
Prognostic impact of EGFR driver mutations on postoperative recurrence in non-small cell lung cancer. T. Okamoto, H. Kitahara , S. Shimamatsu, M. Katsura, K. Takada, T. Fujishita, Y. Suzuki, Y. Morodomi, T. Tagawa, Y. Maehara (Fukuoka, Japan) (10’)
The role of transanal endoscopic microsurgery in rectal tumours: Organ sparing multi-modality treatment. S. Papagrigoriadis (London, UK) (20’)
Neoadjuvant chemoradiotherapy followed by surgery and salvage surgery for the patients with clinical T3/nearly T4 esophageal cancer. H. Saeki, S. Tsutsumi, T. Yukaya, H. Tajiri, Y. Tsuda, Y. Kasagi, Y. Zaits, K. Ando, Y. Nakashim, Y. Imamura, K. Ohgaki, Y. Maehara(Fukuoka, Japan) (10’)
Conservative treatment for patients with osteoid osteoma: A case series. H. Aiba, K. Hayashi, H. Inatani, Y. Satoshi, N. Watanabe, K. Sakurai, H. Tsuchiya, T. Otsuka (Nagoya; Seto, Aichi; Kanazawa, Kanazawa, Japan) (10’)

Chair Persons: T. Okamoto, H. Saeki

Pancreatic neuroendocrine tumors: an overview and algorithm of management. N. Tsoukalas (London, UK) (30’)
Magnetic-guided cancer surgery. M. Ahmed, B. Anninga, M. Douek (London, UK) (20’)
Prognostic factors for long-term survival after distal pancreatectomy for pancreatic adenocarcinoma. a single-centre experience. T. Dumitrascu, S. Dima, C. Stroescu, V. Brasoveanu, L. David, O. Stanciulea, A. Scarlat, V. Herlea, M. Ionescu, I. Popescu (Bucharest, Romania) (15’)
Prognostic factors after surgery for pancreatic neuroendocrine tumors: A single center experience. S.O. Dima, V. Herlea, T. Dumitrascu, C. Stroescu, O. Stanciulea, D. Tomescu, N. Bacalbasa, L. David, F. Botea, R. Purtan, A. Croitoru, C. Gheorghe, I. Popescu (Bucharest, Romania) (15’)
Robotic approach in pancreatic tumors. O. Stanciulea, S. Dima, T. Dumitrascu, I. Popescu (Bucarest, Romania) (15’)
Ureteral reimplantation after resection of alocally invasive in the ureteral ostium cervical tumor – a case report. N. Bacalbasa, S.O. Dima, I. Balescu (Bucharest, Romania) (10’)
The role of extensive upper abdominal surgery in advanced ovarian cancer – a case report. N. Bacalbasa, S.O. Dima, I. Balescu (Bucharest, Romania) (10’)

48. BRAIN CANCER TREATMENT: EPIGENETIC NETWORKS
Special Symposium Organized by E. Benericetti and R. Nano

ROOM D, 8.00-15.00 – Wednesday, October 8

Chair Persons: E. Benericetti, R. Nano, D. Schiffer

Glioblastoma: microenvironment and perivascular and perinecrotic niches. D. Schiffer, L. Annovazzi, C. Casalone, P. Cassoni, M. Mellai (Vercelli, Italy) (40’)
Cytotoxic evaluation of iron nanoparticles covered by rhamnose sugar in glioblastoma and endothelial cell lines. A. Paolini, A. Lascialfari, R. Nano (Pavia; Milan, Italy) (40’)
Glioblastoma stem cells radioresistance: evaluation of the potential benefits from carbon ion irradiation. A. Facoetti, R. Nano (Pavia, Italy) (40’)
DNA damage and repair cascade after chemotherapeutic drugs in glioblastoma cell lines. L. Annovazzi, M. Mellai, V. Caldera, D. Schiffer (Vercelli, Italy) (30’)
Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas. M. Mellai, A. Piazzi, L. Annovazzi, D. Schiffer (Vercelli, Italy) (30’)
Magnetic nanoparticles : recent advances in biomedical applications. P. Arosio, A. Lascialfari, M. Corti, T. Orlando, L. Bordonali, F. Orsini (Milano ; Modena ; Pavia, Italy) (15’)
Epigenetic regulation of tumor growth: micro RNA as biomarkers and possible new drugs. E. Capelli, V. Curti, L. Fassina (Pavia, Italy) (30’)
Survival and danger signals expression in glioblastoma cell lines: tumour immunogenicity after radiation and chemotherapy. F. Pasi, A. Paolini, R. Di Liberto, R. Nano (Pavia, Italy) (40’)
Uptake evaluation of 18f-fluorocholine vs 18f-fluorodeoxyglucose in T98G glioma cells. D. Cappelletti, F.E. Buroni , L. Lodola, M.G. Persico, R. Nano (Pavia, Italy) (30’)

49. CLINICAL CHEMOTHERAPY

ROOM D, 15.15-19.30 – Wednesday, October 8

Chair Persons: T. Aoki, J. Slansky, M. I. Panagiotidis

Novel therapies in soft tissue sarcoma (STS). I. Judson (London, UK)(30’)
Chemotherapy-induced peripheral neuropathy. T. Ohno (Shimabara, Nagasaki, Japan) (30’)
Analysis of complete remission in cases with advanced non-small cell lung cancer. T. Aoki, K. Harada, J. Tanaka, M. Sato, Y. Horio, H. Takiguchi, H. Tomomatsu, K. Tomomatsu, T. Takihara, K. Niimi, N. Hayama, T. Oguma, T. Akiba, T. Komatsu, T. Nakagawa, R. Masuda, T. Urano, E. Kunieda, Y. Oizumi, M. Iwazaki, K. Asano (Isehara, Kanagawa, Japan) (30’)
Therapeutic effectiveness of hyperthermia in malignant melanoma. M.I. Panagiotidis (Edinburgh, Scotland, UK) (40′)
Thyroid disorders as potential predictive clinical marker of better treatment response to sunitnib therapy. D. Kust, M. Prpic, J. Murgic, M. Jazvic, B. Jakšic, D. Krilic, A. Bolanca, Z. Kusic (Zagreb, Croatia) (20’)
Therapeuticstrategies in the 1st line treatment of patients with NSCLC harboring EGFR mutations. A. Rapti (Athens,Greece) (20’)
NBTXR3 nanosized radioenhancer: effective cell killing in the clinic. J. Marill, S. Vivet, P. Zhang, A. Pottier, P. Said, M. Dimitriu (Paris, France) (15’)
Prediction of the fast tumoricide effect of transarterial application of 90-yttrium glass-microspheres, a potential role of dual-energy ct (review). J. Ferda, P. Duras, V. Treška, T. Skalický, J. Fínek, O. Topolcan (Pilsen, Czech Republic) (15’)
AntiHer2 Targeted therapy in advanced gastric cancer. W. Mahfoud, H. Amrani Hassani Joutei, I. Saadaoui, N. Elgnaoui, H. Lebrazi, H. Benomar (Casablanca, Morocco) (10’)

50. PKC SIGNALING IN CANCER
Special Symposium Organized by A.P. Fields

ROOM E, 08.00-12.00 – Wednesday, October 8

Chair Person: A.P. Fields

Tumor suppressor activity of protein kinase C a in epithelial cancers. J.D. Black (Omaha, NE, USA) (30’)
PKCs in vivo function analysed by gene targeting in mice. M. Leitges (Oslo, Norway) (30’)
Protein kinase C delta regulates cell proliferation and cell death. M.E. Reyland, J.M. Symonds, A.M. Ohm (Aurora, CO, USA) (30’)
Targeting atypical protein kinase Cs for pancreatic cancer therapy. N.R. Murray (Jacksonville, FL, USA) (30’)
Protein kinase Cδ signaling mechanisms in lung cancer initiation and maintenance. V. Justilien, M.P. Walsh, S.A. Ali, E.A. Thompson, N.R. Murray, A.P. Fields (Jacksonville, FL, USA) (30’)

51. HEPATOCELLULAR CARCINOMA
Special Symposium Organized by K. Kubota

ROOM E, 13.00-15.00 – Wednesday, October 8

Chair Person: K. Kubota

Anatomical liver resection for hepatocellular carcinoma. K. Kubota, T. Matsumoto (Tochigi, Japan) (20’)
High dorsal rejection of the liver for patients with HCC. T. Takayama (Tokyo, Japan) (20’)
Living donor liver transplantation for patients with HCC in Japan. S. Kawasaki (Tokyo, Japan) (20’)
Therapeutic strategy of hepatocellular carcinoma by laparoscopic hepatetomy. H. Kaneko, Y. Otsuka (Toho, Japan)(20’)
RF ablation for HCC in Japan. R.Tateishi (Tokyo, Japan) (20’)

52. INVASION AND CARCINOMAS OF THE GI TRACT
Special Symposium Organized by O.D. Laerum

ROOM E, 15.10-17.10 – Wednesday, October 8

Chair Person: O.D. Laerum

Introduction. O.D. Laerum (Bergen, Norway)
Expression of the urokinase receptor (UPAR) in gastric adenocarcinomas and non-neoplastic gastric mucosa. W. Alpízar-Alpízar, M. Illemann, M.E. Skindersø, L. Rasmussen, I.J. Christensen, A. Skarstein, K. Ovrebo, I.K. Lund, K.A. Krogfelt, L.P. Andersen, M. Ploug, O.D. Laerum (San José, Costa Rica; Copenhagen, Denmark; Bergen, Norway) (20’)
Molecular biology of colorectal cancer: life after NGS. M. Ilyas (Nottingham, UK) (20’)
Pericellular proteolysis generated by tumour-associated macrophages and fibroblasts is a hallmark of invasive colorectal cancer. M. Illemann (Copenhagen, Denmark) (20’)
Importance of plasminogen activator receptor ( uPAR) for the spread of esophageal adenocarcinomas as compared to other carcinomas of the GI tract. O.D. Laerum (Bergen, Norway) (40’)

53. DRUG RESISTANCE IN CANCER AND TARGETING DNA REPAIR PATHWAYS
Special Symposium Organized by S. Mitra and B. Kaina

ROOM E, 17.20-19.30 – Wednesday, October 8

Chair Persons: S. Mitra, B. Kaina

Exploring DNA repair as a target in cancer therapy. S. Adhikari, M.L. Hegde, S. Mitra (Houston, TX, USA) (40’)
DNA Repair and radiation and drug sensitivity of human blood cell populations. B. Kaina, M. Bauer, D. Heylmann, V. Ponath, M. Eich (Mainz, Germany) (30’)
RECQ1 mediates cancer cell resistance to combination therapy of PARP inhibitor and alkylating chemotherpeutic agents. R. Roy (Washington, DC, USA) (40’)

54. BIOBANKS: A RESEARCH INFRASTRUCTURE FOR THE FUTURE OF TRANSLATIONAL AND CLINICAL RESEARCH
Special Symposium of the International Society for Biological and Environmental Repositories (ISBER), Organized by F. Betsou and F. Guadagni

ROOM F, 8.00-14.00 – Wednesday, October 8

Chair Persons: F. Guadagni, E. Briasoulis
Introduction : F. Guadagni

Biobank standardization and the ISBER contributions. F. Betsou (Luxembourg) (25’)
Establishing a quality-oriented Academic Cancer Biobank: an interdisciplinary initiative of the University of Ioannina, Greece. E. Briasoulis, E. Hatzimichael, A. Dasoula, I. Sainis, Y.C. Stamatiou, M. Fatouros (Ioannina; Rio, Patras, Greece) (25’)
An Italian experience in biobanking research: the involvement of BioBIM in inter-regional research projects. F. Guadagni (Rome, Italy) (25’)
Lifecycle of specimens and data intelligence in a biobank: some models and case studies with BioBIM. U. Nanni (Rome, Italy) (25’)

Chair Persons: F. Betsou, M. Roselli

Conclusion : F. Betsou

55. HYPOXIA AND CANCER CELL PROTECTION IN CANCER METASTASIS
Special Symposium Organized by G. Rutterman

ROOM F, 14.15-18.30 – Wednesday, October 8

Chair Persons: G. Rutteman, J.T. de Oliveira

Stromal hypoxia and metastasis in breast cancer. H. Rundqvist, C. Stockmann, C. Branco-Price, A. Doedens, R.S. Johnson (Cambridge, UK; Stockholm, Sweden; Essen, Germany) (30’)
Elucidating the role of MUC1 in modulating pancreatic cancer cell survival by metabolomic analysis under hypoxic conditions. N.V. Chaika, T. Gebregiworgis, K. Mehla, V. Gunda, R. Powers, P.K. Singh (Omaha, NE, USA) (40’)
Inhibition of mTOR stimulates WNT activity and MUC1 expression in mammary carcinoma cell lines. J.A. Mol, E. Timmermans-Sprang, A. Gracanin (Utrecht, The Netherlands) (25’)
A truncated active form of VDAC1 is associated with hypoxic cell survival and correlates with tumor progression in lung cancer patients. M.C. Brahimi-Horn, N.M. Mazure (Nice, France) (30’)
Hypoxia up-regulates galectin-3 in mammary tumor progression and metastasis. J.T. de Oliveira, C. Ribeiro, G.R. Rutteman, F. Gärtner (Porto, Portugal; Utrecht, The Netherlands) (20’)
Sialylation dynamics in the microenvironment of mammary tumours – sialidase uncloaking. J.T. de Oliveira, F. Gärtner (Porto, Portugal) (20’)
The HIF-1 target Lysyl oxidase promotes survival and outgrowth of colon cancer cells in the bone marrow, enabling bone metastasis formation. C. Reynaud, L. Ferreras, P. Clézardin (Lyon, France) (25’)